Skip to main content
. 2021 Apr 3;21:158–170. doi: 10.1016/j.omto.2021.03.015

Figure 1.

Figure 1

Orelabrutinib inhibited B cell lymphoma cell proliferation in vitro

(A) B cell lymphoma cell lines (TMD8, HBL-1, SU-DHL-6, WSU-NHL, Mino, Z138, and Raji) were treated with indicated concentrations of orelabrutinib (Orel) or ibrutinib (IBR) for 72 h. Cell viability was measured by Cell Titer-Glo luminescent cell viability assay. Data are shown as mean ± SD of three biological replicates. (B) Western blot analysis for phosphorylation levels of Bruton’s tyrosine kinase (BTK) and its related signaling pathway proteins in Z138 and HBL-1 cells after IBR or Orel treatment for 2 h. (C) The relative phosphorylation levels of signaling proteins from three biologically repeated experiments were quantified by measuring the relative intensity of phosphorylated bands to the β-actin bands. ∗p < 0.05 and ∗∗p < 0.01 compared with control group.